Gillian McGovern, Editor

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Josean Gonzalez, PharmD, BCPP, discusses the expanding role of pharmacists in Alzheimer disease care, Baptist Health South Florida’s multidisciplinary approach, and the promise of emerging therapies for patients with cognitive disorders.

Both slow and fast transition periods were safe and effective, with minimal adverse events.

Erica Marini, PharmD, and guest, Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments including a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on anti-amyloid therapies.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

Real-world data reveal that moderate to severe depression is linked to poor control and adherence, and women are more likely to be impacted.

The approval is supported by data from the phase 3 TROPION-Breast02 trial.

This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.

GLP-1 receptor agonists may reduce asthma flare-ups in nondiabetic adults with obesity, hinting at anti-inflammatory benefits.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

Three psychiatric pharmacists highlight trends in psychiatric pharmacotherapy that were shared at the AAPP 2026 Annual Meeting.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Pharmacists can counter misinformation on SSRIs with evidence-based antidepressant guidance, safe tapering advice, and patient-centered depression care.

Efficacy and safety were evaluated in the phase 3 IMvigor011 trial.

Maroney discussed the pharmacist’s role in patient education, safe medication management, and incorporating broader treatment strategies into individualized mental health care plans.

FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.

The ruling comes after weeks of uncertainty for patients, health care providers, and pharmacists about how and whether they could access and distribute the drug.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

The study authors also emphasized that close monitoring during gabapentinoid treatment is necessary, and concomitant use with opioids or benzodiazepines should be avoided.

PMOS to replace PCOS, highlighting metabolic and endocrine roots and a 3-year global rollout aimed at faster diagnosis and better care.

Pharmacists are vital in identifying at-risk patients, supporting diagnostic testing, optimizing therapy, and monitoring medication adjustments.

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.